High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 Rituximab

被引：0
|
作者：
W. Becker
Th. Behr
机构：
[1] Department of Nuclear Medicine,
[2] University of Göttingen,undefined
[3] Germany,undefined
[4] e-mail: wbecker@med-uni-goettingen.de,undefined
[5] Phone: +49/551/39-8510,undefined
[6] Fax: +49/51/39-8526,undefined
来源：
Annals of Hematology | 2001年 / 80卷 / Suppl 3期
关键词：
Lymphoma; High Dose Radioimmunotherapy;
D O I：
10.1007/PL00022777
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：B130 / B131
相关论文
共 50 条
  • [41] Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab
    A J Davies
    Oncogene, 2007, 26 : 3614 - 3628
  • [42] Iodine-131 - Anti-B1 radioimmunotherapy for B-cell lymphoma
    Kaminski, MS
    Zasadny, KR
    Francis, IR
    Fenner, MC
    Ross, CW
    Milik, AW
    Estes, J
    Tuck, M
    Regan, D
    Fisher, S
    Glenn, SD
    Wahl, RL
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 1974 - 1981
  • [43] I-131 Tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: Radiation dose to the testes
    Hattori, Naoya
    Gopal, Ajay
    Fisher, Darrell
    Durack, Lawrence
    Shields, Andrew
    Press, Oliver
    Rajendran, Joseph
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [44] High dose 131I anti-CD20 radioimmunotherapy for relapsed or refractory mantle cell lymphoma:: Radiation absorbed dose evaluation.
    Rajendran, JG
    Eary, JF
    Gopal, AK
    Durack, LD
    Bush, SA
    Press, OW
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 157P - 157P
  • [45] A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
    Tuscano, Joseph M.
    Maverakis, Emanual
    Groshen, Susan
    Tsao-Wei, Denice
    Luxardi, Guillaume
    Merleev, Alexander A.
    Beaven, Anne
    DiPersio, John F.
    Popplewell, Leslie
    Chen, Robert
    Kirschbaum, Mark
    Schroeder, Mark A.
    Newman, Edward M.
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7004 - 7013
  • [46] SUVmax predicts survival in patients with diffuse large B-cell lymphoma who received radioimmunotherapy using 131I-rituximab as consolidation therapy
    Choi, J.
    Lim, I.
    Byun, B.
    Kim, B.
    Choi, C.
    Lim, S.
    Shin, D.
    Kang, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S777 - S778
  • [47] High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥60 years old with relapsed or refractory B-cell lymphoma
    Gopal, Ajay K.
    Rajendran, Joseph G.
    Gooley, Ted A.
    Pagel, John M.
    Fisher, Darrell R.
    Petersdorf, Stephen H.
    Maloney, David G.
    Eary, Janet F.
    Appelbaum, Frederick R.
    Press, Oliver W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) : 1396 - 1402
  • [48] Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab
    Tadahiko Igarashi
    Tomoko Ohtsu
    Hirofumi Fujii
    Yasutsuna Sasaki
    Yasuo Morishima
    Michinori Ogura
    Yoshitoyo Kagami
    Tomohiro Kinoshita
    Masaharu Kasai
    Yoshio Kiyama
    Yukio Kobayashi
    Kensei Tobinai
    International Journal of Hematology, 2001, 73 : 213 - 221
  • [49] Re-treatment of relapsed indolent B-cell lymphoma with rituximab
    Igarashi, T
    Ohtsu, T
    Fujii, H
    Sasaki, Y
    Morishima, Y
    Ogura, M
    Kagami, Y
    Kinoshita, T
    Kasai, M
    Kiyama, Y
    Kobayashi, Y
    Tobinai, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 73 (02) : 213 - 221
  • [50] Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma
    Vacirca, J. L.
    Acs, P. I.
    Shimkus, B. J.
    Rosen, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345